IO Biotech, Inc. (IOBT) — Institutional Holders, Q1 2026
12 institutional investment managers reported a IOBT position on SEC Form 13F-HR for the quarter ended March 31, 2026, with a combined reported value of $199.0K. Every filer is listed below, ranked by position value. Put and call option positions are excluded, and a firm filing several lots or share classes is shown once with its total.
IOBT in Q1 2026: what funds did
Funds that filed a 13F for both Q4 2025 and Q1 2026, by what they did with the common stock. Share counts are adjusted for any split between the two quarters; dollar figures are the change in shares at this quarter’s price.
Biggest buyers
- GSA CAPITAL PARTNERS LLPNew · +348,352 sh+$20.4K
- XTX Topco LtdAdded · +249,928 sh+$14.7K
- JANE STREET GROUPNew · +57,974 sh+$3.4K
- MILLENNIUM MANAGEMENTAdded · +55,442 sh+$3.3K
Biggest sellers
- Novo A/SSold out · -2,512,453 sh-$147.5K
- BANK OF AMERICASold out · -799,953 sh-$47.0K
- Beacon Pointe AdvisorsTrimmed · -463,400 sh-$27.2K
- Dauntless Investment GroupSold out · -451,641 sh-$26.5K
- MORGAN STANLEYTrimmed · -332,967 sh-$19.5K
IOBT 13F holders ranked 1–12 of 12
| # | Institution | Shares | Value | % of portfolio | QoQShares vs Q4 2025 |
|---|---|---|---|---|---|
| 1 | Ikarian Capital#1 · 1,386,565 sh | 1,386,565 | $81.4K | — | 0.0% |
| 2 | BOOTHBAY FUND MANAGEMENT#2 · 451,852 sh | 451,852 | $26.5K | — | 0.0% |
| 3 | GSA CAPITAL PARTNERS LLP#3 · 348,352 sh | 348,352 | $20.0K | — | New |
| 4 | MARSHALL WACE, LLP#4 · 301,291 sh | 301,291 | $18.1K | — | -29.8% |
| 5 | XTX Topco Ltd#5 · 265,792 sh | 265,792 | $15.6K | — | +1575.4% |
| 6 | MORGAN STANLEY#6 · 206,215 sh | 206,215 | $12.1K | — | -61.8% |
| 7 | MILLENNIUM MANAGEMENT#7 · 194,158 sh | 194,158 | $11.4K | — | +40.0% |
| 8 | CITIGROUP#8 · 72,495 sh | 72,495 | $4.3K | — | -35.0% |
| 9 | JANE STREET GROUP#9 · 57,974 sh | 57,974 | $3.4K | — | New |
| 10 | Beacon Pointe Advisors#10 · 42,600 sh | 42,600 | $2.5K | — | -91.6% |
| 11 | GEODE CAPITAL MANAGEMENT#11 · 33,307 sh | 33,307 | $2.0K | — | 0.0% |
| 12 | UBS Group AG#12 · 30,980 sh | 30,980 | $1.8K | — | -28.9% |
Funds that sold out of IOBT in Q1 2026 (12)
Held IOBT at the end of Q4 2025 and filed a Q1 2026 13F without it. Not in the list above, because they no longer hold it. Largest prior position first.
| Institution | Shares sold | Value in Q4 2025 |
|---|---|---|
| Novo A/S2,512,453 sh | 2,512,453 | $1.5M |
| BANK OF AMERICA799,953 sh | 799,953 | $486.4K |
| Dauntless Investment Group451,641 sh | 451,641 | $275.0K |
| RENAISSANCE TECHNOLOGIES207,601 sh | 207,601 | $126.4K |
| BRIDGEWAY CAPITAL MANAGEMENT75,000 sh | 75,000 | $45.7K |
| ADAR1 Capital Management49,928 sh | 49,928 | $30.4K |
| TWO SIGMA SECURITIES44,757 sh | 44,757 | $27.3K |
| Hilton Capital Management25,510 sh | 25,510 | $15.5K |
| PKS Advisory Services20,000 sh | 20,000 | $12.2K |
| Virtu Financial19,078 sh | 19,078 | $12.0K |
| Scientech Research11,255 sh | 11,255 | $6.9K |
| SBI Securities , Ltd.122 sh | 122 | $74.00 |
Source: Form 13F-HR filings on SEC EDGAR, Q1 2026. Values are as reported by each manager at quarter end. “% of portfolio” is the position’s share of the manager’s total reported 13F value for the same quarter. “New” means the manager filed a 13F for Q4 2025 without this position; a dash means no comparison is available. Where a manager’s own filing is internally inconsistent its value is withheld and it is listed last. 13F data shows reported holdings, not recommendations.